Table 3.
Outcomes of key studies evaluating the right therapy for advanced gastroesophageal adenocarcinoma in different lines.
| Trial/line | Arms | n | Outcome |
|---|---|---|---|
| Cunningham et al61/first line | ECF vs. ECX vs. EOF vs. EOX | 1002 | Median OS, 9.9 vs. 9.9 vs. 9.3 vs. 11.2 months; P > 0.05 |
| Kang et al62/first line | XP vs. FP | 316 | Median OS, 10.5 vs. 9.3 months; HR, 0.85; 95% CI: 0.64–1.13; P = 0.008 |
| Koizumi et al63/first line | S1+cisplatin vs. S1 | 305 | Median OS, 13 vs. 11 months; HR, 0.77; 95% CI: 0.61–0.98; P = 0.04 |
| Al-Batran et al65/first line | FLO vs. FLP | 220 | Median OS, 10.7 vs. 8.8 months; P > 0.05 |
| Dank et al67/first line | IF vs. CF | 333 | Median OS, 9 vs. 8.7 months; HR, 1.08; 95% CI: 0.86–1.35; P = 0.53 |
| Van Cutsem et al68/first line | DCF vs. CF | 445 | Median OS, 9.2 vs. 8.6 months; HR, 1.29; 95% CI: 1.0–1.6; P = 0.02 |
| Guimbaud et al69/first line | ECX vs. FOLFIRI | 416 | Median OS, 9.5 vs. 9.7 months; HR, 1.01; 95% CI: 0.82–1.24; P = 0.95 |
| Bang et al70/first line | Trastuzumab + CF vs. CF | 594 | Median OS, 13.8 vs. 11.1 months; HR, 0.74; 95% CI: 0.60–0.91; P = 0.0046 |
| Wilke et al78/second line | Ramucirumab + paclitaxel vs. placebo + paclitaxel | 665 | Median OS, 9.6 vs. 7.4 months; HR, 0.807; 95% CI: 0.678–0.962; P = 0.017 |
| Hironaka et al80/second line | Paclitaxel vs. irinotecan | 223 | Median OS, 9.5 vs. 8.4 months; HR, 1.13; 95% CI: 0.86–1.49; P = 0.38 |
| Li et al81/third line and more | Apatinib vs. placebo | 267 | Median OS, 6.5 vs. 4.7 months; HR, 0.709; 95% CI: 0.537–0.937; P = 0.0156 |
| Kang et al86/third line and more | Nivolumab vs. placebo | 493 | Median OS, 5.26 vs. 4.14 months; HR, 0.63; 95% CI: 0.51–0.78; P < 0.0001 |
ECF: epirubicin, cisplatin, and 5-fluorouracil; ECX: epirubicin, cisplatin, and capecitabine; EOF: epirubicin, oxaliplatin, and 5-fluorouracil; EOX: epirubicin, oxaliplatin, and capecitabine; OS: overall survival; XP: capecitabine and cisplatin; FP: 5-fluorouracil and cisplatin; HR: hazard ratio; CI: confidence interval; FLO: 5-fluorouracil, leucovorin, and oxaliplatin; FLP: 5-fluorouracil, leucovorin, and cisplatin; IF: irinotecan and 5-fluorouracil; CF: cisplatin plus 5-fluorouracil; DCF: docetaxel, cisplatin, and 5-fluorouracil; FOLFIRI: 5-fluorouracil, leucovorin, and irinotecan.